FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

																			1	
1. Name and Address of Reporting Person*  Carey John F						2. Issuer Name and Ticker or Trading Symbol TransMedics Group, Inc. [ TMDX ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
	-									37		(give title		Other (	· I					
(Last)	•	rst) (		3. Date of Earliest Transaction (Month/Day/Year) 09/01/2022								X	below) below)  VP of Operations				Specify			
C/O TRA	ANSMEDIC	CS GROUP, INC			001	01/20	,							, r or operations						
200 MIN																				
		_   4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable								
(Street)														Line)	Form t	filed by One	. Don	ortina Doros		
ANDOV	ER M	A	01810										X Form filed by One Reporting Person							
					-									Form filed by More than One Reporting Person						
(City)	(S	tate) (	(Zip)			l Classif														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Da			Date	e nth/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.			4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a		and 5) Securition Benefici Owned I		es ally Following	Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	ction(s)			(Instr. 4)		
Common Stock			09/01/	2022				M <sup>(1)</sup>		3,000	A	\$2	.21	3,	,771		D			
Common	Common Stock 09/01/2				2022	022		<b>S</b> <sup>(1)</sup>		1,301	D	\$50	.71(2)	2,	2,470		D			
Common Stock 09/01/2				2022	022			S <sup>(1)</sup>		1,699	D	\$51.38(3)		771			D			
		Т	able II								posed of				wned					
				(e.g., p	outs,	calls	, wa	rrants	s, optic	ons,	converti	ble seci	uritie	s)						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	on Date,		Transaction Code (Instr.		n of		Exerci on Da Day/Yo		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		ity D Si (li	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amou or Numb of Share	er						
Stock Option (Right to Buy)	\$2.21	09/01/2022			M <sup>(1)</sup>			3,000	(4)		06/22/2027	Common Stock	3,00	00	\$0.00	2,784		D		

## **Explanation of Responses:**

- 1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$50.09 to \$51.00, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$51.10 to \$51.83, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
- 4. The option is fully vested.

## Remarks:

/s/ Stephen Gordon, as 09/02/2022 attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.